AF
LABP

Amalgamated Financial’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

Amalgamated Financial’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1K Buy
+80
New +$2.03K ﹤0.01% 2993

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Amalgamated Financial's LABP Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Landos Biopharma, Inc. Common Stock (LABP) in Q1 2022: 80 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2993 among its holdings.

45 funds tracked by Wall St. Rank hold LABP as of Q1 2022.

  • Amalgamated Financial held 80 shares of Landos Biopharma, Inc. Common Stock worth $1K as of Q1 2022.
  • Landos Biopharma, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
  • Landos Biopharma, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2993 holding.
  • 45 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.